Oxygen-Generating Scaffolds for Cardiac Tissue Engineering Applications
Source abstract
Abstract
Homogeneous vascularization of implanted tissue constructs can extend to 5 weeks, during which cell death can occur due to inadequate availability of oxygen. Researchers are engineering biomaterials that generate and release oxygen in a regulated manner, in an effort to overcome this hurdle. A main limitation of the existing oxygen-generating biomaterials is the uncontrolled release of oxygen, which is ultimately detrimental to the cells. This study demonstrates the incorporation of calcium peroxide (CaO2) within a hydrophobic polymer, polycaprolactone (PCL), to yield composite scaffolds with controlled oxygen release kinetics sustained over 5 weeks. Oxygen-generating microparticles coencapsulated with cardiomyocytes in a gelatin-based hydrogel matrix can serve as model systems for cardiac tissue engineering. Specifically, the results reveal that the oxygen-generating microspheres significantly improve the scaffold mechanical strength ranging from 5 kPa to 35 kPa, have an average scaffold pore size of 50–100 μm, swelling ratios of 33.3–29.8%, and degradation with 10–49% remaining mass at the end of a 48 h accelerated enzymatic degradation. The oxygen-generating scaffolds demonstrate improvement in cell viability, proliferation, and metabolic activity compared to the negative control group when cultured under hypoxia. Additionally, the optimized oxygen-generating constructs display no cytotoxicity or apoptosis. These oxygen-generating scaffolds can possibly assist the in vivo translation of cardiac tissue constructs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Tissue Engineering and Regenerative Medicine · Bone Tissue Engineering Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Biomedical Engineering and Biotechnology Program, University of Massachusetts Lowell, One University Avenue, Lowell, Massachusetts 01854, United States
Department of Chemical Engineering, University of Massachusetts Lowell, One University Avenue, Lowell, Massachusetts 01854, United States
Department of Surgery, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, Massachusetts 01605, United States
Funding
American Heart Association
References (60)
Show source-provided references
1. Transplantation, U. S. G. I. o. O. D. a. Organ Donation Statistics. https://www.organdonor.gov/statistics-stories/statistics.html (accessed July).
2. 10.2147/IPRP.S13308810.2147/IPRP.S133088 ↗
3. 10.1021/acsbiomaterials.6b0010910.1021/acsbiomaterials.6b00109 ↗
4. Mavroudis C. · 2020 · 41310.1007/978-3-030-14163-9_21 ↗
5. 10.1111/tri.1343210.1111/tri.13432 ↗
6. 10.1111/ajt.1548610.1111/ajt.15486 ↗
7. 10.1080/09506608.2018.146094310.1080/09506608.2018.1460943 ↗
8. 10.1039/C9BM00434C10.1039/C9BM00434C ↗
9. 10.1177/088391151987608010.1177/0883911519876080 ↗
10. 10.1021/acsbiomaterials.9b0051510.1021/acsbiomaterials.9b00515 ↗
11. 10.1038/s41427-019-0166-210.1038/s41427-019-0166-2 ↗
12. 10.1016/j.ajo.2020.11.00110.1016/j.ajo.2020.11.001 ↗
13. 10.1016/j.ijhydene.2020.10.18010.1016/j.ijhydene.2020.10.180 ↗
14. 10.1172/JCI20052440810.1172/JCI200524408 ↗
15. Chandy T. · 2020 · 29710.1016/B978-0-08-102680-9.00012-3 ↗
16. 10.1039/D0BM02048F10.1039/D0BM02048F ↗
17. 10.1002/term.293210.1002/term.2932 ↗
18. 10.1002/pi.450210.1002/pi.4502 ↗
19. 10.1002/adfm.20191081110.1002/adfm.201910811 ↗
20. 10.1088/1758-5090/ac2f8110.1088/1758-5090/ac2f81 ↗
21. 10.1002/adhm.20200169310.1002/adhm.202001693 ↗
22. 10.1016/j.cobme.2017.12.00310.1016/j.cobme.2017.12.003 ↗
23. 10.1002/smll.20190505510.1002/smll.201905055 ↗
24. 10.1016/j.cobme.2021.10026310.1016/j.cobme.2021.100263 ↗
25. 10.1016/j.energy.2018.12.05610.1016/j.energy.2018.12.056 ↗
26. 10.3389/fendo.2020.0005710.3389/fendo.2020.00057 ↗
27. 10.1111/nph.1642410.1111/nph.16424 ↗
28. 10.1038/s41551-020-0539-410.1038/s41551-020-0539-4 ↗
29. 10.1016/j.ces.2018.02.04410.1016/j.ces.2018.02.044 ↗
30. 10.1016/j.tibtech.2016.05.01210.1016/j.tibtech.2016.05.012 ↗
31. 10.1088/1758-5090/ab332a10.1088/1758-5090/ab332a ↗
32. 10.1016/j.bioactmat.2021.11.00210.1016/j.bioactmat.2021.11.002 ↗
33. 10.1016/j.biomaterials.2008.09.06510.1016/j.biomaterials.2008.09.065 ↗
34. 10.1016/j.ijbiomac.2019.04.15910.1016/j.ijbiomac.2019.04.159 ↗
35. 10.1016/j.ijpharm.2021.12059510.1016/j.ijpharm.2021.120595 ↗
36. 10.1016/j.colsurfb.2021.11185010.1016/j.colsurfb.2021.111850 ↗
37. Keilin D. · Proc. R. Soc. London, Ser. B · 1938 · 124 · 39710.1098/rspb.1938.0001 ↗
38. 10.1021/acsami.6b1551510.1021/acsami.6b15515 ↗
39. 10.1007/s12274-021-3480-210.1007/s12274-021-3480-2 ↗
40. 10.1002/fft2.4410.1002/fft2.44 ↗
41. Arunachalam K. · 2021 · 310.1007/978-1-0716-1233-0_2 ↗
42. 10.1101/pdb.prot09549710.1101/pdb.prot095497 ↗
43. 10.32933/ActaInnovations.26.510.32933/ActaInnovations.26.5 ↗
44. 10.1016/j.jhazmat.2022.12832310.1016/j.jhazmat.2022.128323 ↗
45. 10.1074/jbc.M116.75182610.1074/jbc.M116.751826 ↗
46. 10.1016/j.bbamcr.2019.03.00710.1016/j.bbamcr.2019.03.007 ↗
47. 10.1016/j.eujim.2021.10208310.1016/j.eujim.2021.102083 ↗
48. 10.1007/s10565-022-09773-710.1007/s10565-022-09773-7 ↗
49. Jurisic V. · Adv. Cancer Biomarkers · 2015 · 11510.1007/978-94-017-7215-0_8 ↗
50. 10.1016/j.tibtech.2021.01.00710.1016/j.tibtech.2021.01.007 ↗
51. 10.1016/j.msec.2021.11189610.1016/j.msec.2021.111896 ↗
52. 10.1002/pi.460810.1002/pi.4608 ↗
53. 10.3390/antiox906056010.3390/antiox9060560 ↗
54. 10.2478/pjct-2019-004610.2478/pjct-2019-0046 ↗
55. 10.1039/C5RA16023E10.1039/C5RA16023E ↗
56. 10.2337/diabetes.53.5.133610.2337/diabetes.53.5.1336 ↗
57. 10.1111/iej.1360310.1111/iej.13603 ↗
58. 10.1007/s10266-015-0213-610.1007/s10266-015-0213-6 ↗
59. 10.1016/j.joen.2007.09.01210.1016/j.joen.2007.09.012 ↗
60. 10.1021/acsabm.9b0020510.1021/acsabm.9b00205 ↗